Depression and addiction comorbidity: Towards a common molecular target?;Comorbidité entre la dépression et l'addiction: Vers une cible moléculaire commune?

Medecine/Sciences

Volumn 31, Issue 5, 2015, Pages 546-550

  Arango Lievano, Margarita ^a   Kaplitt, Michael G ^b  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; COCAINE; LIPOCORTIN 2; NERVE PROTEIN; NEUROTRANSMITTER RECEPTOR; PROTEIN S 100; S100 CALCIUM BINDING PROTEIN A10;

ANHEDONIA; ANIMAL; APPETITE; CHOLINERGIC NERVE CELL; COMORBIDITY; DEFICIENCY; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; INTERNEURON; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NERVE TRACT; NUCLEUS ACCUMBENS; OPTOGENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; PLEASURE; PREVALENCE; PROTEIN TRANSPORT; REWARD; RNA INTERFERENCE; SUBSTANCE-RELATED DISORDERS; THERAPEUTIC USE;

ANHEDONIA; ANIMALS; ANNEXIN A2; APPETITIVE BEHAVIOR; CHOLINERGIC NEURONS; COCAINE; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERNEURONS; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; NUCLEUS ACCUMBENS; OPTOGENETICS; PLEASURE; PREVALENCE; PROTEIN TRANSPORT; RECEPTORS, NEUROTRANSMITTER; REWARD; RNA INTERFERENCE; S100 PROTEINS; SUBSTANCE-RELATED DISORDERS;

EID: 84931071539     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20153105017     Document Type: Review

References (27)

1. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse 1995; 7 : 481-97.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National comorbidity survey replication (NCS-R). JAMA 2003; 289 : 3095-105.
3. Swendsen JD, Merikangas KR. The comorbidity of depression and substance use disorders. Clin Psychol Rev 2000; 20 : 173-89.
4. Vialou V. Dépression et régulation de l'activité dopaminergique. Med Sci (Paris) 2013; 29 : 473-7.
5. Volman SF, Lammel S, Margolis EB, et al. New insights into the specificity and plasticity of reward and aversion encoding in the mesolimbic system. J Neurosci 2013; 33 : 17569-76.
6. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006; 29 : 565-98.
7. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci 2013; 14 : 609-25.
8. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 2012; 35 : 68-77.
9. Bewernick BH, Hurlemann R, Matusch A, et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2010; 67 : 110-6.
10. Kuhn J, Moller M, Treppmann JF, et al. Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction. Mol Psychiatry 2014; 19 : 145-6.
11. Aouizerate B, Martin-Guehl C, Cuny E, et al. Stimulation cérébrale profonde du striatum ventral dans le traitement du trouble obsessionnel-compulsif avec dépression majeure. Med Sci (Paris) 2005; 21 : 811-3.
12. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002; 53 : 590-605.
13. rd, Chaudhury D, et al. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 2010; 330 : 385-90.
14. Hikida T, Kimura K, Wada N, et al. Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior. Neuron 2010; 66 : 896-907.
15. Bertran-Gonzalez J, Bosch C, Maroteaux M, et al. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 2008; 28 : 5671-85.
16. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311 : 77-80.
17. Warner-Schmidt JL, Flajolet M, Maller A, et al. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci 2009; 29 : 1937-46.
18. Svenningsson P, Kim Y, Warner-Schmidt J, et al. p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci 2013; 14 : 673-80.
19. Alexander B, Warner-Schmidt J, Eriksson T, et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2010 ; 2 : 54ra76.
20. Warner-Schmidt JL, Schmidt EF, Marshall JJ, et al. Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. Proc Natl Acad Sci USA 2012; 109 : 11360-5.
21. Le Moine C, Tison F, Bloch B. D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum. Neurosci Lett 1990; 117 : 248-52.
22. Nelson AB, Hang GB, Grueter BA, et al. A comparison of striatal-dependent behaviors in wild-type and hemizygous Drd1a and Drd2 BAC transgenic mice. J Neurosci 2012; 32 : 9119-23.
23. Arango-Lievano M, Schwarz JT, Vernov M, et al. Cell-type specific expression of p11 controls cocaine reward. Biol Psychiatry 2014; 76 : 794-801.
24. Gong S, Doughty M, Harbaugh CR, et al. Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J Neurosci 2007; 27 : 9817-23.
25. Chen G, Twyman R, Manji HK. p11 and gene therapy for severe psychiatric disorders: a practical goal? Sci Transl Med 2010 ; 2 : 54ps1.
26. Dugué GP, Tricoire L. Principes et applications de l'optogénétique en neuroscience. Med Sci (Paris) 2015; 31 : 291-303.
27. Vandecasteele M, Senova YS, Palfi S, Dugué GP. Potentiel thérapeutique de la neuromodulation optogénétique. Med Sci (Paris) 2015; 31 : 404-16.